Original Source(s)
Related Content
Can Proteomics Refine Lung Screening?
Proteomic biomarkers improve short-term lung cancer risk assessment.
June 1, 2026
-
5 min
FDA Approves Cefepime-Zidebactam Injection
Phase 3 ENHANCE-1 results showed higher composite clinical cure and microbiologic response rates with cefepime-zidebactam vs meropenem in hospitalized adults with complicated urinary tract infection or acute pyelonephritis.
June 3, 2026
-
2 min